Immatics N.V. Biotechnologies aus Tübingen

Eine Kooperation mit einem Hersteller wird ausgebaut:

https://investors.immatics.com/news-releases/...cturing-collaboration

 

Immatics: könnte wesentlich weiter sein, als der Markt die Gesellschaft zur Zeit bewertet
siehe Anlage
https://www.express.de/ratgeber/gesundheit/...s-leben-rettet-37147834  

Diese Behandlung hat aber nichts mit Immatics zu tun, sondern mit einer der vielen anderen Hopp-Projekte https://dietmar-hopp-stiftung.de/medizin/...hung-gegen-den-brustkrebs

(Aber am Ende profitieren natürlich diese Projekte und Immatics auch untereinander voneinander)
 

https://investors.immatics.com/news-releases/...ion-its-adoptive-cell

Aug 18, 2020
Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) --

-First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial
-German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical
 ACTengine® trial in Germany investigating Immatics’ IMA203 product candidate
-Three clinical trial sites in Germany have started recruiting patients for Immatics’ ACTengine® IMA200 trial

...
 

Mal spaßeshalber das 1. Immatics-Chartbild... Stundenkerzen..
Ändert sich tatsächlich die Richtung ? Volumen lässt allerdings nach..
 

sprach/spricht auf der CAR-TCR DigitalWeek;
https://car-tcr-digital-week.com/program/full-event-guide/
--
Steffen Walter, Chief Technology Officer, Immatics
TCR-T Therapies Using Novel Solid Cancer Targets
• Assess the discovery, characterization and engineering of TCRs using the XCEPTORTM platform directed against novel targets derived from the XPRESIDENT® platform
• Preclinical Update on Immatics’ ACTengine® program IMA204
--
Ali Mohamed Vice President, Chemistry,Manufacturing & Control, Immatics
17.09.2020 / 11.05 2.05
Manufacturing Platforms for Endogenous, Engineered, Autologous or Allogeneic TCR-T based Adoptive Cell Therapies
• Extensive process development led to the manufacturing approaches for the various product platforms
• Exemplary manufacturing and/or clinical data from various trials will be presented for the various platforms
--  

https://investors.immatics.com/news-releases/...e-eliot-forster-board
 

Wenn ich mir die Entwicklung anschaue bekomme ich nur schlechte Laune. Das Marketing ist schlecht bzw. nicht vorhanden. Sehen wir bald die 6,xx Euro?
Schaut euch bitte mal den Spread an....

63 % meiner Investition ist bereits weg....

Wie seht Ihr die mittelfristige und langfristige Entwicklung?

 

Ja, auch das Volumen sinkt weiter. Nur noch Mini-Umsätze, auch an der Nasdaq.

Selbst so wichtige News, wie die vom 10.09.2020 über Präklinik-Daten zu IMA204, verpuffen komplett.
https://investors.immatics.com/news-releases/...-cell-therapy-program
(IND für 2021 geplant)

TCR ist als Thema insgesamt nicht im Fokus. Wenn sich das mal ändert, z.B. durch (Klinik-)Erfolge von Adaptimmune, dann sollte der ganze Sektor mehr Beachtung finden.

Erstaunlich ist aber für mich nach wie vor die hohe Marktkapitalisierung von Immatics (466Mio.) gegenüber z.B. nur 112 Mio. von Medigene. Ich hoffe aber mal, dass MDG unterbewertet ist und nicht Immatics überbewertet.. (Habe sie beide)

Ich sehe es langfristig ..

https://immatics.com/our-pipeline/

 

Zarter Versuch einer Wende..
(Nasdaq, Stundenkerzen)

 

am 16.12.2020 beim Cell Therapy Analytical Development Summit
https://cell-therapy-analytics.com/program/full-event-guide/

"Donor Selection for Allogeneic T Cell Therapy
• Regulatory/legal/ethical aspects of donor selection for an allogeneic T-cell program
• Characterization of starting material and donor characteristics impacting the quality of immune cells
• Defining donor suitability based on evaluation in manufacturing process"



 

Zwischendurch waren es schon +10%.
Scheint zu klappen mit der Wende (#35)

https://www.nasdaq.com/market-activity/stocks/imtx
 

Warum ist eigentlich der Spread bei uns so hoch?

Würde mir das bitte einer mal erklären.

Vielen Dank  

Der Hauptbörsenplatz für Immatics ist die Nasdaq !

Hier in Deutschland wurden heute nur 597 Stück gehandelt. Da kann man keinen normalen Spread erwarten. Es gibt doch fast kein Angebot und fast keine Nachfrage. Da handelt vermutlich meist der MarketMaker mit sich selber.
 

 

 

Wenn die Goldmänner 17$ sagen, dann läuft's :)  

https://investors.immatics.com/news-releases/...ief-financial-officer

Kein Unbekannter... Früher u.a. bei Inflarx und Medigene..
 

nicht so peppig wie andere aber sehr informativ  

hier die update Empfehlung von GS heute morgen auf Nasdaq

Immatics (IMTX)
Combining the discovery of true targets for cancer immunotherapies (therapies that utilize the power of the immune system) with the development of the right T cell receptors, Immatics hopes to ultimately enable a robust and specific T cell response against these targets. Based on its cutting-edge approach, Goldman Sachs counts itself as a fan.
Writing for the firm, analyst Graig Suvannavejh notes that unlike CAR-T approaches, a T cell receptor (TCR)-based approach can go after targets inside the cell, and fight the 90% of cancers which are solid tumor in nature. The company is advancing two technologies: ACTengine, designed for personalized TCR-based cell therapies, and TCER, which targets TCR-based bispecific antibodies.
ACTengine is the more advanced technology, with its four assets IMA201, a genetically engineered T cell product candidate that targets melanoma-associated antigen 4 or 8, IMA202, which targets melanoma-associated antigen 1, IMA203, which targets preferentially expressed antigen in melanoma (PRAME) and IMA204 that targets COL6A3 (found in a tumor’s stroma and is highly prevalent in the tumor microenvironment/TME in a broad range of cancers) expected to enter the clinic soon.
Using the TCER platform, IMTX is developing IMA401 and IMA402, or “off-the-shelf” biologics consisting of a portion of the TCR which directly recognizes cancer cells and a T cell recruiter domain which recruits and activates the patient’s T cells.
Speaking to the market opportunity, Suvannavejh mentioned, “Cancer immunotherapies have made great strides over the past decade, and in particular, advances seen with CAR-T have paved the way for cell therapy-based approaches... CAR-T, however, has to date only shown limited effect in treating cancers that are solid tumor in nature. With more than 90% of all cancers being solid tumors — with lung, breast, colorectal and prostate cancers accounting for c.60% of the total — this is the opportunity for IMTX.” To this end, he believes cumulative 2035 sales could land at $15.5 billion for the ACTengine-based assets.
Reflecting another positive, since 2017, IMTX has inked at least one significant partnership per year with top global biopharma companies. According to Suvannavejh, each provided non-dilutive funding opportunities.
The analyst added, “...the ARYA Sciences Acquisition Corporation, a special purpose acquisition company (SPAC), merger that enabled IMTX to become a publicly traded entity brought in a deep roster of well-known, experienced healthcare-dedicated institutional investors. Taken together, we find these to be validating of IMTX’s longer-term prospects.”
Looking ahead, the initial clinical data readouts for IMA201, IMA202 and IMA203, which are slated for Q1 2021, and investigational new drug (IND) application submissions for IMA204 and IMA401 in 2021 and YE2021, respectively, reflect key potential catalysts, in Suvannavejh’s opinion.
Everything that IMTX has going for it convinced Suvannavejh to reiterate his Buy rating. Along with the call, he attached a $17 price target, suggesting 73% upside potential. (To watch Suvannavejh’s track record, click here)
Are other analysts in agreement? They are. Only Buy ratings, 4, in fact, have been issued in the last three months. Therefore, the message is clear: IMTX is a Strong Buy. Given the $19 average price target, shares could soar 93% in the next year. (See Immatics stock analysis on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
 

Hier noch der Link dazu;
https://www.nasdaq.com/articles/...ally-for-these-3-stocks-2020-09-30
 

 

BO über Immatics und die anderen US-Notierten Biotechs
https://www.boerse-online.de/nachrichten/aktien/...tscheck-1029634672
 

Stunden-Chart
 

Jetzt seit 3 Tagen auch auf Tradegate mal mit richtigem Volumen !